These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22811222)

  • 21. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unravelling the role of denosumab in prostate cancer.
    Aragon-Ching JB
    Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
    [No Abstract]   [Full Text] [Related]  

  • 25. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
    Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Physiopathology, diagnosis and management of bone metastases from prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S349-56. PubMed ID: 19070815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Zoledronic acid in the treatment of prostate cancer].
    Conti G
    Minerva Urol Nefrol; 2005 Dec; 57(4):313-7. PubMed ID: 16247352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F; Abrahamsson PA; Miller K
    BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reply to F. Valcamonico et al.
    Smith MR; Halabi S; Small EJ
    J Clin Oncol; 2014 Nov; 32(32):3685. PubMed ID: 25225438
    [No Abstract]   [Full Text] [Related]  

  • 32. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
    Coleman RE
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Patients with prostate cancer bone metastases: can bisphosphonates help?].
    Krabbe LM
    Urologe A; 2019 Mar; 58(3):314-318. PubMed ID: 30767031
    [No Abstract]   [Full Text] [Related]  

  • 34. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.
    Smith MR
    J Urol; 2003 Dec; 170(6 Pt 2):S55-7; discussion S57-8. PubMed ID: 14610411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Zoledronic acid and osseous pathologies in the course of neoplasia. Part II].
    Caffo O
    Tumori; 2005; 91(6):suppl 23-7. PubMed ID: 16457163
    [No Abstract]   [Full Text] [Related]  

  • 36. [Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases].
    Musaev TN; Kerimov AKh; Ali-zade AM
    Georgian Med News; 2008 Nov; (164):14-8. PubMed ID: 19075335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone continuum of cancer.
    Lipton A
    Am J Clin Oncol; 2010 Jun; 33(3 Suppl):S1-7. PubMed ID: 20526089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.